SGLT2 inhibitors and GLP-1 receptor agonists: the definitive combination?

Lancet Diabetes Endocrinol. 2024 Aug;12(8):507-508. doi: 10.1016/S2213-8587(24)00183-9. Epub 2024 Jul 8.
No abstract available

MeSH terms

  • Diabetes Mellitus, Type 2* / drug therapy
  • Drug Therapy, Combination
  • Glucagon-Like Peptide-1 Receptor Agonists*
  • Humans
  • Hypoglycemic Agents* / therapeutic use
  • Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

  • Sodium-Glucose Transporter 2 Inhibitors
  • Hypoglycemic Agents
  • Glucagon-Like Peptide-1 Receptor Agonists